Description
A virtual platform that integrates various patient information (body size, age, genetic background, disease characteristics) to evaluate potential clinical scenarios and determine actionable dosing recommendations tailored to each patient's needs in pediatrics
Market positioning
Academic medical center leader in pediatric precision dosing
Target audience
Pediatricians, neonatologists, clinical pharmacologists, and healthcare providers treating pediatric patients
Use cases
Precision dosing for pediatric patients across multiple therapeutic areas including mTOR inhibitors, biologics, immunosuppressives, opioids, and anti-infectious drugs
Company information
Company size
Academic medical center or small-to-medium healthcare technology organization
Revenue
UNKNOWN
Scale
Regional to national academic medical center reach
Number of users
UNKNOWN
Features
Pricing
Rating
Pros and cons
Based on: (AI summary)
Pros
- Comprehensive patient data integration
- Real-time dosing recommendations
- Evidence-based approach with published research
- Multi-therapeutic area coverage
- Integration with clinical workflows
Cons
- Limited to Cincinnati Children's Hospital
- Requires specialized expertise to operate
- May have limited scalability to other institutions
- Dependent on availability of patient data
Feature Comparison
Top features across 5 competitors (most common first)
| Feature | PrecisePK T… | Simcyp Pedi… | Clinical Ph… | Model-Infor… | Physiologic… |
|---|---|---|---|---|---|
| immunosuppressives | |||||
| biologics | |||||
| Acute Kidney Injury (AKI) prediction tool | |||||
| Bayesian-guided precision dosing | |||||
| Model-Informed Precision Dosing (MIPD) | |||||
| Multi-language support (English | |||||
| Spanish | |||||
| Chinese | |||||
| Thai | |||||
| Korean) | |||||
| Multiple drug modules | |||||
| Real-time monitoring and analytics | |||||
| SOC2 and ISO/IEC 27001 compliance | |||||
| Vancomycin AUC dosing calculator | |||||
| Advanced PBPK modeling and simulation | |||||
| Pediatric population modeling | |||||
| Diverse population analysis | |||||
| Drug behavior prediction | |||||
| Advanced simulation capabilities | |||||
| Regulatory-ready modeling |